Genmab — December 2023
-
-
For os her på PI har Genmab vel været en no-brainer i laang tid så godt at se det også er ved at gå op for nogle af analytikerne. Der har jo i bund og grund ikke været dårligt nyt fra Genmab efter kursen var 3300 og alle analytikerne havde targets over 3000. Den eneste FA ændring er vel den høje rente.
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody
CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL) -
or as Abbvie states "This data may support investigating optimized step-up dose in an outpatient setting." https://news.abbvie.com/2023-12-09-New-Data-for-Bispecific-Antibody-Epcoritamab-DuoBody-R-CD3xCD20-Shows-Strong,-Durable-Treatment-Response-for-Patients-with-Difficult-To-Treat-Relapsed-Refractory-R-R-Follicular-Lymphoma-FL?utm_campaign=generic&utm_medium=social&utm_source=TW&utm_content=other&sf270770143=1
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind